Ian Edward Smith

Q: What Schools Are Affiliated With Ian Edward Smith

Ian Edward Smith is affiliated with the following schools: Massachusetts General Hospital, Université libre de Bruxelles, University of Warwick, University of Southern Denmark, Institute of Cancer Research, University of Nottingham, University of Oxford, University of Edinburgh

Ian Edward Smith's AcademicInfluence.com Rankings

Ian Edward Smith

Philosophy

#4539

World Rank

#7097

Historical Rank

Logic

#1967

World Rank

#2852

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Ian Edward Smith's Degrees

Doctorate Medicine Stanford University

Why Is Ian Edward Smith Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Ian Edward Smith's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials (2005) (6940)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. (2005) (4911)
Triple-negative breast cancer. (2010) (1781)
A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. (2005) (1554)
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial (2007) (1499)
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. (2011) (1439)
Aromatase inhibitors in breast cancer. (2003) (928)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. (2007) (890)
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer (2015) (844)
Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. (2005) (710)
11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial (2017) (656)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (2018) (639)
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. (2011) (618)
Proliferation marker Ki-67 in early breast cancer. (2005) (610)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial (2018) (587)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer. (2007) (579)
Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics (2008) (544)
Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. (2009) (486)
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial (2013) (449)
Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer (2015) (426)
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? (2004) (420)
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. (2002) (390)
Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. (2007) (379)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. (2014) (379)
Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment. (1992) (376)
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. (2008) (358)
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. (2011) (358)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. (2018) (353)
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer (2000) (338)
Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. (2001) (322)
Triple negative breast cancer: molecular profiling and prognostic impact in adjuvant anthracycline-treated patients (2008) (321)
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial. (2016) (317)
Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. (2005) (308)
Nurse led follow up and conventional medical follow up in management of patients with lung cancer: randomised trial (2002) (297)
Basal-like breast carcinomas: clinical outcome and response to chemotherapy (2006) (297)
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer (2010) (288)
Preoperative chemotherapy in patients with resectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review (2007) (277)
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists. (2005) (271)
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer (2009) (254)
Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer (2004) (253)
Chemotherapy for breast cancer during pregnancy: an 18-year experience from five London teaching hospitals. (2005) (251)
Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer (2010) (247)
Breast cancer and pregnancy. (2005) (239)
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. (2014) (225)
Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II (2004) (215)
Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group (2020) (207)
Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01). (2014) (202)
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens. (1993) (197)
Breast cancer in adolescents and young women. (2003) (195)
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. (2008) (194)
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer. (2007) (194)
Platinum-based chemotherapy in triple-negative breast cancer. (2008) (193)
Circulating tumour cells in breast cancer. (2004) (192)
Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] (2006) (191)
High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. (1995) (188)
Symptom relief with MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in advanced non-small-cell lung cancer. (1995) (184)
Detection of circulating epithelial cells in the blood of patients with breast cancer: comparison of three techniques (2005) (183)
Growth of human tumour cell colonies from biopsies using two soft-agar techniques. (1978) (182)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial (2009) (180)
Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer. (2019) (176)
Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012) (2015) (174)
Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. (2016) (170)
Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC). (2009) (164)
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. (2009) (161)
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence. (2016) (157)
Noninvasive Detection of HER2 Amplification with Plasma DNA Digital PCR (2013) (157)
Mitoxantrone (novantrone): a review of experimental and early clinical studies. (1983) (157)
Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer. (1985) (155)
Studies of apoptosis in breast cancer (2001) (151)
Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. (2003) (149)
Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer (2010) (146)
Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial. (1981) (146)
Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. (2006) (144)
PREVENTION OF ISOPHOSPHAMIDE-INDUCED UROTHELIAL TOXICITY WITH 2-MERCAPTOETHANE SULPHONATE SODIUM (MESNUM) IN PATIENTS WITH ADVANCED CARCINOMA (1980) (142)
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. (2006) (139)
Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. (2008) (136)
Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. (2011) (136)
Incidence, pattern and timing of brain metastases among patients with advanced breast cancer treated with trastuzumab (2006) (135)
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. (1993) (135)
Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer (1997) (135)
FAILURE OF CHEMOTHERAPY TO PROLONG SURVIVAL IN A GROUP OF PATIENTS WITH METASTATIC BREAST CANCER (1980) (131)
Marrow autotransplantation accelerates haematological recovery in patients with malignant melanoma treated with high-dose melphalan. (1979) (130)
Vinorelbine – a clinical review (2000) (130)
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. (2013) (127)
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. (2007) (127)
Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer (2009) (121)
BIG 1-98: Randomized double-blind phase III study to evaluate letrozole (L) vs. tamoxifen (T) as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer (2005) (118)
Molecular Profiling of Aromatase Inhibitor–Treated Postmenopausal Breast Tumors Identifies Immune-Related Correlates of Resistance (2013) (116)
Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer (2007) (114)
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. (1998) (113)
Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. (1994) (112)
Autocrine function for insulin-like growth factor I in human small cell lung cancer cell lines and fresh tumor cells. (1990) (110)
Neoadjuvant chemotherapy for breast cancer (2000) (110)
Mortality within 30 days of chemotherapy: a clinical governance benchmarking issue for oncology patients (2006) (109)
Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the breast international group 1-98 trial. (2012) (108)
First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. (2011) (108)
Aminoglutethimide in the treatment of advanced postmenopausal breast cancer. (1982) (105)
Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group stage C neuroblastoma. (1991) (102)
Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. (2010) (100)
Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? (2003) (100)
Cell filtration‐laser scanning cytometry for the characterisation of circulating breast cancer cells (2003) (99)
Intratumoral Estrogen Disposition in Breast Cancer (2010) (99)
Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging. (1994) (99)
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer. (1987) (96)
Pathological complete response and residual DCIS following neoadjuvant chemotherapy for breast carcinoma (2006) (96)
Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer (2006) (95)
Efficacy and safety of Herceptin® in women with metastatic breast cancer: results from pivotal clinical studies (2001) (94)
Early changes in apoptosis and proliferation following primary chemotherapy for breast cancer (2003) (93)
Primary medical (neo-adjuvant) chemotherapy for operable breast cancer. (1993) (92)
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study. (2017) (92)
Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. (1982) (92)
Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer. (1989) (92)
Does timing of adjuvant chemotherapy for early breast cancer influence survival? (2003) (91)
High incidence of HER-2 positivity in inflammatory breast cancer. (2004) (91)
Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. (1999) (89)
Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. (1993) (88)
Mammography in the assessment of response to medical treatment of large primary breast cancer. (1993) (88)
Prognostic factors in small cell lung cancer: a simple prognostic index is better than conventional staging. (1987) (87)
Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. (1998) (86)
Comparison of anastrozole vs tamoxifen alone and in combination as neoadjuvant treatment of estrogen receptor-positive operable breast cancer in postmenopausal women The IMPACT Trial (2003) (86)
Correction: Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026] (2006) (86)
AMINOGLUTETHIMIDE IN TREATMENT OF METASTATIC BREAST CARCINOMA (1978) (86)
The pathway study: results of a pilot feasibility study in patients suspected of having lung carcinoma investigated in a conventional chest clinic setting compared to a centralised two-stop pathway. (2003) (80)
Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. (1993) (80)
Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen. (1994) (80)
A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma (2000) (80)
Goals of Treatment for Patients With Metastatic Breast Cancer. (2006) (78)
Coordinate expression of apoptosis-associated proteins in human breast cancer before and during chemotherapy. (2002) (78)
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer. (2011) (77)
Preoperative/neoadjuvant medical therapy for early breast cancer. (2001) (77)
Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (EBC) (2008) (76)
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. (2017) (76)
The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis (2006) (76)
Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients. (1984) (76)
Somatomedin-C/insulin-like growth factor-I is a mitogen for human small cell lung cancer. (1988) (75)
A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy (2005) (74)
Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin. (1987) (74)
In vitro radiation response of cells from four human tumors propagated in immune-suppressed mice. (1978) (73)
Experimental and clinical studies with somatostatin analogue octreotide in small cell lung cancer. (1991) (71)
Cisplatin and its analogues in the treatment of advanced breast cancer: a review. (1992) (69)
Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. (2006) (67)
A phase II study of pemetrexed disodium (LY231514) in patients with locally recurrent or metastatic breast cancer. (2001) (66)
years versus 1 year of adjuvant trastuzumab for HER 2-positive breast cancer ( HERA ) : an open-label , randomised controlled trial (2013) (66)
Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. (2013) (64)
Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial (2020) (64)
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. (2015) (64)
A novel continuous infusional 5-fluorouracil-based chemotherapy regimen compared with conventional chemotherapy in the neo-adjuvant treatment of early breast cancer: 5 year results of the TOPIC trial. (2004) (64)
Carboplatin, etoposide, and ifosfamide as intensive chemotherapy for small-cell lung cancer. (1990) (62)
Mechanisms of resistance to aromatase inhibitors (2005) (62)
Clinical benefit from palliative chemotherapy in non-small-cell lung cancer extends to the elderly and those with poor prognostic factors. (1998) (61)
Status of adjuvant endocrine therapy for breast cancer (2014) (61)
Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance (2005) (60)
Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial. (2013) (59)
Morbidity of cranial relapse in small cell lung cancer and the impact of radiation therapy. (1986) (59)
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients (2018) (59)
In vitro and in vivo radiosensitivity of human tumour cells obtained from a pancreatic carcinoma xenograft (1976) (58)
Research needs in breast cancer (2016) (57)
LOW-DOSE AMINOGLUTETHIMIDE IN TREATMENT OF ADVANCED BREAST CANCER (1984) (57)
Breast radiotherapy after lumpectomy--no longer always necessary. (2004) (55)
Anthrapyrazole CI941: a highly active new agent in the treatment of advanced breast cancer. (1991) (54)
Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial (2011) (54)
Is there still a role for neoadjuvant therapy in breast cancer? (2003) (54)
VP 16-213 in acute myelogenous leukaemia (1976) (53)
The value of computed tomographic (CT) scan surveillance in the detection and management of brain metastases in patients with small cell lung cancer. (1990) (53)
A colony-forming assay for human tumour xenografts using agar in diffusion chambers. (1976) (53)
Control of aromatase in breast cancer cells and its importance for tumor growth (1993) (52)
First-Line Bevacizumab-Containing Therapy for Triple-Negative Breast Cancer: Analysis of 585 Patients Treated in the ATHENA Study (2012) (52)
Aminoglutethimide in the treatment of advanced breast cancer. (1984) (51)
Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. (1997) (50)
Primary medical therapy for operable breast cancer. (1989) (50)
Management of small HER2-positive breast cancers. (2010) (49)
AUTOLOGOUS BONE MARROW RESCUE IS UNNECESSARY AFTER VERY-HIGH-DOSE CYCLOPHOSPHAMIDE (1983) (48)
Association between breast cancer subtypes and response to neoadjuvant anastrozole (2011) (48)
A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. (2014) (48)
Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group. (1996) (48)
A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. The Granisetron Study Group. (1990) (48)
Multimodality therapy in inflammatory breast cancer: is there a place for surgery? (2000) (48)
Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer. (1999) (47)
Challenges in the endocrine management of breast cancer. (2003) (47)
Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer. (1981) (46)
Abstract S5-2: HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-positive early breast cancer at 8 years of median follow up (2012) (46)
First-line bevacizumab-containing therapy for breast cancer: results in patients aged≥70 years treated in the ATHENA study. (2012) (46)
Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer. (2019) (45)
Endocrine changes with the aromatase inhibitor fadrozole hydrochloride in breast cancer. (1994) (45)
Phase II study of the antifolate N10-propargyl-5,8-dideazafolic acid (CB 3717) in advanced breast cancer. (1988) (44)
Vindesine: a phase II study in the treatment of breast carcinoma, malignant melanoma, and other tumors. (1978) (44)
Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer, and Prognostic Implications in Residual Disease (2016) (42)
Endocrine therapy for advanced/metastatic breast cancer. (2013) (41)
Letrozole versus tamoxifen in the treatment of advanced breast cancer and as neoadjuvant therapy (2003) (41)
Adjuvant aminoglutethimide for postmenopausal patients with primary breast cancer: analysis at 8 years. (1992) (40)
Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer (2011) (40)
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). (2005) (40)
[Breast cancer in the early stage]. (2012) (39)
Controversies in the management of patients with breast cancer: adjuvant endocrine therapy in premenopausal women. (2008) (39)
Pre-operative chemotherapy in early stage resectable non-small-cell lung cancer: a randomized feasibility study justifying a multicentre phase III trial (1999) (39)
Efficacy and safety of trastuzumab (2004) (38)
A phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. (1996) (38)
BIG 1-98: A randomized double-blind phase III study evaluating letrozole and tamoxifen given in sequence as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. (2009) (38)
The role of ipsilateral breast radiotherapy in management of occult primary breast cancer presenting as axillary lymphadenopathy. (2011) (38)
First-line chemotherapy rechallenge after relapse in small cell lung cancer (2004) (38)
Phase II trial of carboplatin (JM8) in treatment of patients with malignant mesothelioma (2004) (37)
Comparative effects of anastrozole, tamoxifen alone and in combination on plasma lipids and bone-derived resorption during neoadjuvant therapy in the impact trial. (2005) (37)
An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. (1992) (37)
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. (2014) (37)
Screening for lung cancer: time to think positive (1999) (36)
Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer (2013) (36)
The palliative benefits of MVP (mitomycin C, vinblastine and cisplatin) chemotherapy in patients with malignant mesothelioma. (2004) (36)
Relationship between estrogen receptor, progesterone receptor, HER-2 and Ki67 expression and efficacy of aromatase inhibitors in advanced breast cancer. (2011) (36)
Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients (2012) (36)
High dose versus low dose medroxyprogesterone acetate: a randomized trial in advanced breast cancer. (1987) (35)
Symptoms of endocrine treatment and outcome in the BIG 1-98 study (2013) (35)
Mesenteric desmoid tumours in Gardner's syndrome--review of medical treatments. (1989) (35)
A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. The Granisetron Study Group. (1993) (34)
Serum p53 antibodies: predictors of survival in small-cell lung cancer? (2000) (34)
Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer. (1987) (34)
Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial. (2013) (34)
Predictors of response to aromatase inhibitors (2007) (33)
Maximizing clinical benefit with trastuzumab. (2004) (33)
A randomised comparative trial of mitozantrone/methotrexate/mitomycin C (MMM) and cyclophosphamide/methotrexate/5 FU (CMF) in the treatment of advanced breast cancer. (1991) (33)
Randomized phase II trial of infusional fluorouracil, epirubicin, and cyclophosphamide versus infusional fluorouracil, epirubicin, and cisplatin in patients with advanced breast cancer. (1998) (32)
Therapeutic effects of the aromatase inhibitor fadrozole hydrochloride in advanced breast cancer. (1996) (32)
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation (2016) (32)
Prevention of doxorubicin-induced alopecia by scalp hypothermia: relation to degree of cooling (1982) (31)
Acute Chemotherapy–Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom (2006) (31)
Long-term outcome of HER2 positive metastatic breast cancer patients treated with first-line trastuzumab. (2015) (31)
Occult primary breast carcinoma presenting as axillary lymphadenopathy. (2002) (30)
A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. (2002) (30)
Mitoxantrone (Novantrone) as single agent and in combination chemotherapy in the treatment of advanced breast cancer. (1983) (30)
Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer. (1985) (30)
Three years' experience with Ch1VPP (a combination of drugs of low toxicity) for the treatment of Hodgkin's disease. (1979) (30)
Abstract S1-01: The association between event-free survival and pathological complete response to neoadjuvant lapatinib, trastuzumab or their combination in HER2-positive breast cancer. Survival follow-up analysis of the NeoALTTO study (BIG 1-06) (2013) (29)
Nuclear NF-κB/p65 expression and response to neoadjuvant chemotherapy in breast cancer (2010) (29)
Chemotherapy of human breast-carcinoma xenografts. (1980) (29)
Correction to: De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017 (Annals of Oncology (2017) 28(8) (1700–1712), (S0923753419321817), (10.1093/annonc/mdx308)) (2017) (29)
Long-term survival five years or more after combination chemotherapy and radiotherapy for small cell lung carcinoma. (1981) (29)
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy (2015) (28)
A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer. (1991) (27)
Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039) (2014) (27)
SYMPTOMATIC HYPOCALCAEMIA AFTER TREATMENT WITH HIGH-DOSE AMINOHYDROXYPROPYLIDENE DIPHOSPHONATE (1987) (27)
Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule. (1984) (27)
How should cancer presenting as a malignant pleural effusion be managed? (1996) (27)
Medical treatment of early breast cancer. IV: neoadjuvant treatment (2006) (27)
Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study. (2000) (26)
Adjuvant treatment in breast cancer (1992) (26)
Abstract GS1-03: Peri-operative aromatase inhibitor treatment in determining or predicting longterm outcome in early breast cancer – The POETIC* Trial (CRUK/07/015) (2018) (26)
Inflammatory breast cancer—The Royal Marsden Hospital experience (2010) (26)
Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen. (1996) (25)
Factors determining outcome after third line chemotherapy for metastatic breast cancer. (2007) (25)
Regression of carcinoid tumour with cyproheptadine. (1982) (25)
Clinical and immunological assessment of Mycobacterium vaccae (SRL172) with chemotherapy in patients with malignant mesothelioma (2002) (25)
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition (2014) (25)
Role of Herceptin® in Primary Breast Cancer: Views from North America and Europe (2001) (25)
ENCEPHALOPATHY WITH RAPID INFUSION IFOSFAMIDE/MESNA (1987) (25)
Phase II trial of topotecan administered as a 21-day continuous infusion in previously untreated patients with stage IIIB and IV non-small-cell lung cancer. (1998) (25)
Aromatase inhibitors: a dose-response effect? (1999) (25)
Plastic mattresses and sudden infant death syndrome (1995) (24)
High-dose cyclophosphamide (7 g/m2) with or without autologous bone marrow rescue after conventional chemotherapy in the treatment of patients with small cell lung cancer. (1983) (24)
Therapy Insight: anthracyclines and trastuzumab—the optimal management of cardiotoxic side effects (2008) (24)
Ultrasound assessment of residual abnormalities following primary chemotherapy for breast cancer. (1997) (24)
Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go? (2007) (24)
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas (2016) (24)
Mitoxantrone: An active new agent in the treatment of advanced breast cancer (2004) (23)
UFT/leucovorin plus bolus epirubicin and cyclophosphamide in advanced/metastatic breast cancer. (2000) (23)
Sanctuary site leptomeningeal metastases in HER-2 positive breast cancer: A review in the era of trastuzumab. (2016) (23)
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy. (2015) (23)
The pharmacokinetics of oral lonidamine in breast and lung cancer patients. (1991) (23)
Response to third-line endocrine treatment for advanced breast cancer. (1993) (22)
Hodgkin's Disease in Children (1977) (22)
In vitro effects of substance P analogue [D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P on human tumour and normal cell growth. (1992) (22)
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial. (2016) (22)
Sternal/para-sternal resection for parasternal local recurrence in breast cancer. (2010) (22)
Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience. (2013) (22)
Medical treatment of early breast cancer. I: adjuvant treatment (2006) (22)
A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine. (1982) (22)
Pattern of care in locally advanced breast cancer: focus on local therapy. (2011) (21)
Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer (2014) (21)
S25 Update of the HERA trial and the role of 1 year Trastuzumab as adjuvant therapy for breast cancer (2009) (21)
EPIC: an effective low toxicity regimen for relapsing lymphoma. (1993) (21)
Palliative chemotherapy for advanced non-small cell lung cancer (1994) (21)
Enhancing endocrine response with novel targeted therapies (2008) (20)
JM8 Development and Clinical Projects (1984) (19)
Results of an independent oncology review board of pivotal clinical trials of gemcitabine in non-small cell lung cancer. (1999) (19)
CARDIOTOXICITY ASSOCIATED WITH - MITOXANTRONE (1984) (19)
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic (2020) (19)
Adjuvant tamoxifen for early breast cancer. (1988) (19)
Anastrozole versus tamoxifen as neoadjuvant therapy for oestrogen receptor-positive breast cancer in postmenopausal women: the IMPACT and PROACT trials (2004) (19)
Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: A single-centre experience. (2017) (19)
Who would have thought a single Ki67 measurement would predict long-term outcome? (2009) (18)
Pentamethylmelamine (PMM): Phase I clinical and pharmacokinetic studies. (1983) (18)
Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative: ASCO Guideline Update (2021) (18)
Primary chemotherapy for early breast cancer. (1996) (18)
[D-Arg1, D-Phe5, D-Trp7,9, Leu11] substance P inhibits the growth of human small cell lung cancer xenografts in vivo. (1993) (18)
A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen (2004) (18)
Development and responses of brain metastases during treatment with trastuzumab emtansine (T‐DM1) for HER2 positive advanced breast cancer: A single institution experience (2018) (17)
Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer. (1983) (17)
A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer (2006) (17)
Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors (2019) (17)
The effect of misonidazole on the radiation response of clonogenic human pancreatic carcinoma cells. (1978) (17)
Mitomycin C, vinblastine and cisplatin (MVP): an active and well-tolerated salvage regimen for advanced breast cancer (2005) (17)
Evidence-based guidelines for managing patients with primary ER+ HER2− breast cancer deferred from surgery due to the COVID-19 pandemic (2020) (17)
Quantification by gas chromatography of N,N'-di-(2-chloroethyl)-phosphorodiamidic acid in the plasma of patients receiving isophosphamide. (1980) (17)
A pilot study of MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in small-cell lung cancer. (1998) (16)
The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause (2011) (16)
Pharmacokinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy (2004) (16)
Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? (2011) (16)
Primary medical (neoadjuvant) chemotherapy for operable breast cancer: Building on early promise (1992) (15)
ABC of breast diseases: Role of Systemic Treatment for Primary Operable Breast Cancer (1994) (15)
Small cell carcinoma of the prostate: implications for management. (1991) (15)
Mitoxantrone: A phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours (2004) (15)
Management of breast cancer in older and frail patients. (2015) (14)
Mechanisms of hormone response: a role for apoptosis (1995) (14)
Scalp hypothermia to prevent adriamycin-induced hair loss. (1982) (14)
Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment? (2010) (14)
Combination treatment with tamoxifen and aminoglutethimide in advanced breast cancer. (1983) (14)
Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer (2004) (14)
Aromatase inhibitors--extending the benefits of adjuvant therapy beyond tamoxifen. (2004) (14)
Abstract S6-01:BRCA1methylation status, silencing and treatment effect in the TNT trial: A randomized phase III trial of carboplatin compared with docetaxel for patients with metastatic or recurrent locally advanced triple negative or BRCA1/2 breast cancer (CRUK/07/012) (2017) (14)
Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer. (1985) (14)
Symptoms of endocrine treatment and outcome: A retrospective analysis of the monotherapy arms of the BIG 1-98 trial. (2011) (13)
Menstrual cycle associated changes in hormone-related gene expression in oestrogen receptor positive breast cancer (2019) (13)
The Effects of Neoadjuvant Anastrozole and Tamoxifen on Circulating Vascular Endothelial Growth Factor and Soluble Vascular Endothelial Growth Factor Receptor 1 in Breast Cancer (2008) (13)
Primary chemotherapy in breast cancer. (1998) (13)
Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy. (1983) (13)
Tamoxifen-induced tumour regression associated with dermatomyositis. (1982) (13)
MMM (mitomycin/mitoxantrone/methotrexate): an effective new regimen in the treatment of metastatic breast cancer. (1993) (13)
Molecular characterisation of aromatase inhibitor-resistant advanced breast cancer: the phenotypic effect of ESR1 mutations (2018) (13)
ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL (2012) (13)
Serum insulin-like growth factor-I levels in patients with small cell lung cancer. (1988) (12)
Signet-ring cell lymphoma of bone marrow. (1994) (12)
PROPHYLACTIC CRANIAL IRRADIATION IN SMALL-CELL LUNG CANCER (1985) (12)
Risk of recurrence estimates with IHC4+C are tolerant of variations in staining and scoring: an analytical validity study (2015) (12)
Hera Trial: 2 Years Versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with Her2-Positive Early Breast Cancer at 8 Years of Median Follow up (2012) (12)
UK guidance document: treatment of metastatic breast cancer. (2012) (12)
Improving the therapeutic index of two alkylating agents. (1980) (12)
Aromatase inhibitors in early breast cancer treatment. (2003) (12)
101. Change in expression of epidermal growth factor receptor and c-erb-B2 during the development of tamoxifen resistance in human breast cancer (1995) (12)
Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study. (2000) (12)
Impact of aromatase inhibitor treatment on global gene expression and its association with antiproliferative response in ER+ breast cancer in postmenopausal patients (2019) (12)
Pivotal trials of letrozole: a new aromatase inhibitor. (1998) (12)
0-73. Pharmacokinetic interaction between letrozole and tamoxifen in postmenopausal patients with advanced breast cancer (1997) (12)
Adjuvant treatment for early breast cancer. (2005) (11)
High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma (2004) (11)
Time Trends in the Outcome of Elderly Patients with Breast Cancer (2008) (11)
CNS relapse despite prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC). (1986) (11)
Aromatase inhibitors in early breast cancer therapy. (2004) (11)
Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer? (2011) (11)
Tracking tumor-specific mutations in circulating-free DNA to predict early relapse after treatment of primary breast cancer. (2014) (11)
Abstract PD5-01: HERA trial: 10 years follow up of trastuzumab after adjuvant chemotherapy in HER2 positive early breast cancer – Final analysis (2016) (11)
Relationship between IHC4 score and response to neo-adjuvant chemotherapy in estrogen receptor-positive breast cancer (2017) (11)
Carboplatin (JM8), etoposide (VP16) and thoracic irradiation for small cell lung cancer (S.C.L.C.): an evaluation of lung toxicity. (1988) (11)
Health related quality of life of women in TEACH, a randomised placebo controlled adjuvant trial of lapatinib in early stage Human Epidermal Growth Factor Receptor (HER2) overexpressing breast cancer. (2015) (10)
Inefficacy of calcipotriol In skin metastases from breast cancer (1993) (10)
Fadrozole and letrozole in advanced breast cancer: Clinical and biochemical effects (2004) (10)
Overview of gemcitabine activity in advanced breast cancer. (2006) (10)
Presurgical (neoadjuvant) endocrine therapy is a useful model to predict response and outcome to endocrine treatment in breast cancer patients (2012) (10)
The optimal duration and selection of adjuvant endocrine therapy for breast cancer: how long is enough? (2014) (10)
First-Line Bevacizumab (Bev) Combination Therapy in Triple-Negative (TN) Locally Recurrent/Metastatic Breast Cancer (LR/MBC): Subpopulation Analysis of Study MO19391 in >2000 Patients (Pts). (2009) (10)
Tumor Ki67 Proliferation Index within 4 Weeks of Initiating Neoadjuvant Endocrine Therapy for Early Identification of Non-Responders. (2009) (10)
Tamoxifen induces the expression of cytoplasmic c-erbB2 immunoreactivity in oestrogen-receptor positive breast carcinomas in-vivo (1993) (10)
New drugs for breast cancer (2002) (10)
Medical treatment of early breast cancer. III: chemotherapy (2006) (10)
Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer (2017) (10)
Chylous ascites in Kaposi's sarcoma: a case report (1992) (10)
Carcinoid tumour presenting as an orbital metastasis. (1981) (10)
Drug therapy: Aromatase inhibitors in breast cancer (2003) (10)
Lymphoma presenting as "Idiopathic" juvenile osteoporosis. (1975) (9)
Autologous bone marrow transplantation and solid tumors (1984) (9)
Agranulocytosis associated with aminoglutethimide: pharmacological and marrow studies. (1986) (9)
Chemotherapy for elderly patients with lung cancer (1995) (9)
Adjuvant endocrine therapy for early breast cancer. (2007) (9)
Neoadjuvant Endocrine Therapy (2004) (9)
Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience (2015) (9)
Abstract PD2-01: Randomized phase 3 trial of adjuvant letrozole versus anastrozole in postmenopausal patients with hormone receptor positive, node positive early breast cancer: Final efficacy and safety results of the femara versus anastrozole clinical evaluation (Face) trial (2016) (9)
Carboplatin in the treatment of metastatic carcinoid tumours and paraganglioma: a phase II study (2008) (9)
S4-7: Results of a Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Adjuvant Lapatinib in Women with Early-Stage ErbB2-Overexpressing Breast Cancer. (2011) (8)
Long-term outcome with targeted therapy in advanced/metastatic HER2-positive breast cancer: The Royal Marsden experience (2019) (8)
More money is needed to care for patients with cancer (1997) (8)
Continuous infusional 5-fluorouracil in breast cancer or the revival of an old drug? (1996) (8)
High dose cyclophosphamide treatment of human oat cell xenografts in immune deprived mice. (1983) (8)
Aminoglutethimide for the treatment of advanced postmenopausal breast cancer. (1983) (8)
Survival outcomes of the NeoALTTO study: Updated results of a randomized multicenter phase III neoadjuvant trial. (2017) (8)
Short term tamoxifen induces the cytoplasmic expression of c-erbB2 and BCL-2 in er-positive human primary breast cancer (1992) (8)
Letter: Mithramycin for hypercalcaemia associated with myeloma and other malignancies. (1975) (8)
A randomised comparative trial of infusional ECisF versus conventional FEC as adjuvant chemotherapy in early breast cancer: the TRAFIC trial. (2010) (8)
Major Impact of Sampling Methodology on Gene Expression in Estrogen Receptor–Positive Breast Cancer (2018) (8)
Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: Updated safety analysis of trial BIG 1–98 (2007) (8)
Patient preference for extended palliative chemotherapy for non-small cell lung cancer (1995) (8)
Carboplatin in small cell lung cancer: the Royal Marsden Hospital experience. (1992) (8)
Relative effectiveness of letrozole alone or in sequence with tamoxifen for patients diagnosed with invasive lobular carcinoma. (2013) (8)
Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical study. (1981) (8)
A comparision of grey-scale ultrasound with other methods for the detection of liver metastases from breast carcinoma. (1976) (8)
Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study (2004) (8)
Mitoxantrone as first-line chemotherapy for advanced breast cancer: results of a European collaborative study. (1984) (8)
Aggressive management of doxorubicin-induced cardiomyopathy associated with 'low' doses of doxorubicin. (1994) (7)
Management of Hodgkin's disease in childhood. (1977) (7)
Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): First results of the MRC LU22/NVALT/EORTC 08012 multi-centre randomised trial (2007) (7)
Future directions in the adjuvant treatment of breast cancer: the role of trastuzumab. (2001) (7)
Adjusting for Selective Crossover in Analyses of Letrozole (Let) Versus Tamoxifen (Tam) in the BIG 1-98 Trial. (2009) (7)
Systematically higher Ki67 scores on core biopsy samples compared to corresponding resection specimen in breast cancer: a multi-operator and multi-institutional study (2022) (7)
Continuous infusional chemotherapy for early breast cancer: the Royal Marsden Hospital experience. (1998) (7)
Effective new low toxicity chemotherapy with carboplatin, vinblastine and methotrexate for small cell lung cancer: a randomised trial against doxorubicin, cyclophosphamide and etoposide. (1991) (7)
Normal tissue toxicity and antitumour experiments carried out in mice using high-dose cyclophosphamide. (1983) (7)
Phase II studies of pemetrexed in metastatic breast and gynecologic cancers. (2004) (7)
Dose intensification of carboplatin and etoposide as first-line combination chemotherapy in small cell lung cancer. (1995) (7)
Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) (2009) (7)
Priming reduces the bone marrow toxicity of carboplatin. (1987) (7)
Trastuzumab after adjuvant chemotherapy in older patients - Reply (2007) (7)
Updated results from the international phase III ALTTO trial (BIG 2-06/Alliance N063D). (2021) (7)
A randomised trial of cyclophosphamide pretreatment ('priming') before short-duration chemotherapy for small cell lung carcinoma. (1985) (7)
Trastuzumab after adjuvant chemotherapy in older patients – Authors' reply (2007) (6)
A double blind randomised clinical trial of adjuvant aminoglutethimide versus placebo given to post menopausal patients with histologically confirmed stage II breast cancer. (1986) (6)
Tryptophan in the treatment of carcinoid crisis (2004) (6)
Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer. (1985) (6)
Which tools can I use in daily clinical practice to improve tailoring of treatment for breast cancer? Treatment decision-making in advanced disease. (2008) (6)
Place of aromatase inhibitors in the endocrine therapy of breast cancer (2001) (6)
Premarin in the management of metastatic breast carcinoma in post-menopausal patients. (1979) (6)
ADRIAMYCIN IN ACUTE LEUKÆMIA (1974) (6)
The evolution of adjuvant endocrine therapy: developments since St Gallen 2005. (2007) (6)
Abstract PD5-07: The impact of early lapatinib-induced rash on disease-free and overall survival in patients treated within the ALTTO phase III randomized trial (2016) (6)
A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial. (2013) (6)
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial (2017) (6)
Primary analysis of study MO19391, an open-label safety study of bevacizumab (B) plus taxane-based therapy as 1st-line treatment of patients (pts) with locally recurrent (LR) or metastatic breast cancer (mBC). (2009) (6)
5017 Multinational study (n = 2041) of first-line bevacizumab (Bev) plus taxane-based chemotherapy (CT) for locally recurrent or metastatic breast cancer (LR/mBC): updated results of MO19391 (2009) (6)
Adjuvant chemotherapy for early breast cancer (1983) (6)
Controversies in the medical management of breast cancer. (1985) (6)
Medical treatment of early breast cancer. II: endocrine therapy (2006) (6)
Chemo- and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2-Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary. (2015) (6)
Small cell lung cancer cell line from histologically and immunocytochemically negative bone marrow. (1990) (6)
A phase II study of Mitomycin C in refractory adcvanced breast cancer. A multi-centre pilot study. (1980) (6)
Follow-up tests to detect recurrent disease: patient's reassurance or medical need? (2013) (5)
New perspectives in lung cancer.5. New drugs in lung cancer. (1992) (5)
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in estrogen receptor-positive breast cancer. (2014) (5)
LHRH analogues in breast cancer: clever, but do we need them? (1991) (5)
Short-term presurgical treatment for all? (2007) (5)
Abstract S2-5: Molecular Profiling of Aromatase Inhibitor-Treated Post-Menopausal Breast Tumours Identifies Determinants of Response (2010) (5)
CARBOPLATIN CHEMOTHERAPY FOR MALIGNANT PARAGANGLIOMA (1986) (5)
CVM versus ACE in the treatment of small cell lung cancer. (1993) (5)
Abstract P2-05-01: Clinico-pathological relationships with Ki67 in POETIC (CRUK/07/015) – Critical lessons for assessing Ki67 for prognosis and as a pharmacodynamic marker (2017) (5)
Adjuvant aminoglutethimide therapy for postmenopausal patients with primary breast cancer: progress report. (1982) (5)
Trastuzumab for early breast cancer (2006) (5)
Navelbine and the anthrapyrazoles. (1994) (5)
0-38. Identification of clinical factors predicting outcome following primary chemotherapy for operable breast cancer (1997) (5)
The impact of giving neo-adjuvant chemotherapy for patients with non-small cell lung cancer (NSCLC) : data from the MRC LU22/NVALT/EORTC 08012 randomised clinical trial (2005) (5)
Plasma calcitonin in small cell lung cancer: prognostic significance. (1983) (5)
Medical management of non-small cell lung cancer. (1995) (5)
Expression of estrogen responsive genes in breast cancers correlates with plasma estradiol levels in postmenopausal women. (2009) (5)
Biological studies in primary medical therapy of breast cancer: The Royal Marsden Hospital experience (1999) (5)
A phase II study of carboplatin and vinorelbine in patients with poor prognosis small cell lung cancer. (2003) (5)
A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer. (2002) (5)
Biomarker changes associated with the development of resistance to aromatase inhibitors (AIs) in ER-positive breast cancer. (2010) (4)
BIG 1-98: A randomized double-blind phase III study comparing letrozole and tamoxifen given in sequence vs. alone as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. (2006) (4)
Comparison of different endocrine therapies in management of bone metastases from breast carcinoma. (1985) (4)
75 Good symptom relief with palliative MVP (mitomycin c, vinblastine, cisplatin) chemotherapy in malignant mesothelioma (1997) (4)
Vindesine in the treatment of breast cancer (2004) (4)
New treatments for small cell lung cancer. When to test. (1989) (4)
A comparison of combination chemotherapy using vindesine or vincristine with adriamycin in the treatment of advanced breast carcinoma. (1980) (4)
Complete excision with narrow margins provides equivalent local control to wider excision in breast conservation for invasive cancer (2018) (4)
Neoadjuvant/presurgical treatments (2008) (4)
SEX HORMONE BINDING GLOBULIN LEVELS AND PROGNOSIS IN EARLY BREAST CANCER (1981) (4)
2123 POSTER MO19391: an open-label safety study of bevacizumab plus taxane monotherapy or in combination as first-line treatment of patients with locally recurrent or metastatic breast cancer (LR or MBC) (2007) (4)
Routine prophylactic granulocyte colony stimulating factor (GCSF) is not necessary with accelerated (dose dense) paclitaxel for early breast cancer (2008) (4)
MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC) (2008) (4)
Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy. (2016) (4)
HIGH-DOSE CARBOPLATIN (JM8) IN PATIENTS WITH LUNG-CANCER - A PHASE-I STUDY (1986) (4)
Prognostic (Px) significance of Ki67 before and after neoadjuvant chemotherapy (CT) in early breast cancer (2007) (4)
Impact of timing of adjuvant chemotherapy for early breast cancer: the Royal Marsden Hospital experience (2021) (3)
Trial of perioperative endocrine therapy: Individualizing care (POETIC). (2011) (3)
Long-term (8 years) assessment of trastuzumab-related cardiac events in the HERA trial. (2013) (3)
Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer (2004) (3)
Survival from breast cancer in England and Wales up to 2001 (2008) (3)
Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. (2005) (3)
A pilot study of mitomycin, cisplatin and continuous infusion 5-fluorouracil (MCF) in advanced non-small-cell lung cancer. (1995) (3)
Pathogenesis of bone metastases in breast cancer (1993) (3)
THIOPROLINE IN SQUAMOUS CELL CANCER (1980) (3)
5PTHE CLINICAL IMPACT OF USING THE IHC4 SCORE: OUR MDT EXPERIENCE IN A PROSPECTIVE SERIES OF POSTMENOPAUSAL WOMEN WITH ER POSITIVE EARLY BREAST CANCER (2014) (3)
Abstract P5-10-06: Risk of recurrence estimates with IHC4 are tolerant of variations in staining and scoring (2015) (3)
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. (2017) (3)
The Growth of Colonies of Human Bone Marrow and Tumour Cells in Soft Agar in Diffusion Chambers (1980) (3)
Patient benefits from new treatment options and schedules for breast cancer. (1997) (3)
A high molecular weight non-bombesin/gastrin releasing peptide growth factor in small cell lung cancer. (1987) (3)
Presurgical progesterone in early breast cancer: so much for so little? (2011) (3)
A PHASE-I HIGH-DOSE ESCALATION STUDY OF CARBOPLATIN (1987) (3)
Failure of intensive combination therapy (cyclophosphamide, adriamycin, 5-fluorouracil) to control adenocarcinoma or large-cell anaplastic carcinoma of lung (2004) (3)
Taxotere is active in small cell lung cancer (SCLC) a phase II trial of the eortc early clinical trials group (ECTG) (1993) (3)
Mitomycin C, vinblastine and carboplatin: effective outpatient chemotherapy for advanced non-small cell carcinoma of the lung (NSCLC). (2001) (3)
Small cell lung cancer as a cause of acute renal failure secondary to bilateral renal infiltration. (2000) (3)
Phase I and pharmacokinetic studies with the pentacyclic pyrroloquinone mitoquidone (2004) (3)
Molecular changes in premenopausal oestrogen receptor-positive primary breast cancer in Vietnamese women after oophorectomy (2017) (3)
A PHASE-II STUDY OF ANTHRAPYRAZOLE CI-941, A HIGHLY-ACTIVE NEW DRUG AGAINST ADVANCED BREAST-CANCER (1990) (3)
Letter: Adriamycin in acute leukaemia. (1974) (2)
De-escalating and escalating systemic therapy of early breast cancer. (2017) (2)
LBA7DISEASE-FREE SURVIVAL (DFS) IN THE LAPATINIB ALONE ARM AND EXPANDED RESULTS OF THE PHASE III ALTTO TRIAL (BIG 2-06; NCCTG (ALLIANCE) N063D) IN THE ADJUVANT TREATMENT OF HER2-POSITIVE EARLY BREAST CANCER (EBC) (2014) (2)
A phase II study of losoxantrone (dup 941) in advanced breast cancer (1993) (2)
Abstract S6-02: Occurrence of natural ESR1 mutations during acquisition of endocrine resistance in breast cancers and widely used ER+ cell lines (2016) (2)
The modulating effects of flurbiprofen on adriamycin plus vincristine or vindesine in the treatment of advanced breast cancer (2004) (2)
MYELOSUPPRESSION AFTER METHOTREXATE, MITOXANTRONE, AND MITOMYCIN C (1987) (2)
Urinary-derived monocyte-colony stimulating factor (P-100) following treatment with carboplatin and etoposide in small cell lung cancer (SCLC). (1993) (2)
Haemolytic uraemic syndrome in a patient with lung cancer: further evidence for a toxic interaction between mitomycin-C and tamoxifen. (1996) (2)
Impact of Duration of Neoadjuvant Aromatase Inhibitors on Molecular Expression Profiles in Estrogen Receptor–positive Breast Cancers (2021) (2)
Intercalated radio-chemotherapy in small cell lung cancer: toxicity and implications for future regimens. (1991) (2)
Abstract 926: ESR1 mutations evolve during the treatment of metastatic breast cancer, and detection in ctDNA predicts sensitivity to subsequent hormone therapy (2015) (2)
Adjuvant lapatinib in women with early-stage HER2-positive breast cancer (HER2+ BC): Analysis of the hormone receptor-negative subgroup of the intent-to-treat (ITT) population of the TEACH trial. (2012) (2)
Aromatase Inhibitors Reduce the Expression of a Hypoxia Metagene in Oestrogen Receptor Positive Breast Cancer in Postmenopausal Women. (2009) (2)
Abstract PD07-07: Prediction of antiproliferative response to lapatinib by HER3 in an exploratory analysis of HER2-non-amplified (HER2−) breast cancer in the MAPLE presurgical study (CRUK E/06/039) (2012) (2)
Assessment of lipids and bone-derived resorption products during neoadjuvant therapy with anastrozole (A), v tamoxifen (T), v combination (C) in the IMPACT trial. (2004) (2)
Trastuzumab and other novel therapies in breast cancer (2006) (2)
PG 13.02 Management of breast cancer in older and frail patients (2015) (2)
Targeting HER2 in the adjuvant setting: dealing with new standards and with open questions. (2009) (2)
Leukaemia and lymphomas in childhood. (1977) (2)
Abstract 536: Molecular residual disease detection in early stage breast cancer with a personalized sequencing approach (2021) (2)
Lack of Correlation between Genetic Polymorphisms in Tamoxifen Metabolizing Enzymes with Primary Endpoints in the IMPACT Trial. (2009) (2)
A solitary bone lesion in a patient with previous breast cancer and the importance of bone biopsy: a case report and a review of guidelines. (2013) (2)
Progression of endocrine therapies for breast cancer: where are we headed? (2007) (2)
43PDevelopment and validation of multiplex digital PCR assays on circulating tumor DNA in advanced breast cancer: Implementation for clinical routine use (2015) (2)
S41 Targeting HER2 in the adjuvant setting: Dealing with new standards and open questions (2009) (2)
Metastatic orchioblastoma: alpha1-fetoprotein in diagnosis and combination chemotherapy in treatment: a case report. (1977) (2)
The viability of marrow stored at 4oC (1984) (2)
The Extended Adjuvant Treatment Strategy in Early Breast Cancer (2006) (2)
Preventing late recurrence in hormone receptor-positive early breast cancer: a review. (2022) (1)
Polymorphisms of the aromatase gene (CYP19A1) and benefit of aromatase inhibitors (AIs) in metastatic breast cancer (mBC) patients. (2011) (1)
Immunohistochemical Phenotype after 20-Year Follow-Up of the Royal Marsden Tamoxifen Breast Cancer Prevention Trial (RMTBCPT). (2009) (1)
First-line bevacizumab-containing therapy for breast cancer: results in patients aged ≥70 years treated in the ATHENA study. (2012) (1)
Severe synergistic toxicity from docetaxel in a patient treated concurrently with protease inhibitors as part of HIV post-exposure prophylaxis: a case report (2009) (1)
PD05-06: Determination of HER2 Status with Analysis of Plasma DNA by Digital PCR in Patients with Metastatic Breast Cancer. (2011) (1)
A study of factors determining outcome of patients receiving third line chemotherapy for metastatic breast cancer: The Royal Marsden Hospital experience. (2006) (1)
High dose chemotherapy and autologous bone marrow rescue in the treatment of breast cancer (1992) (1)
A PHASE II STUDY OF CONTINUOUS LOW DOSE THALIDOMIDE IN PATIENTS WITH RENAL CELL. MELANOMA, OVARIAN AND BREAST CANCER (1999) (1)
Choosing treatment for metastatic breast cancer (1983) (1)
A Control Randomised Trial Comparing Vindesine and Adriamycin with Vincristine and Adriamycin in the Treatment of Advanced Breast Carcinoma (1981) (1)
Primary/Neoadjuvant Chemotherapy for Early Breast Cancer (1997) (1)
Correlation between experimentally and clinically demonstrated activity of two new cytotoxic agents in breast cancer. (1985) (1)
The follow-up of women at high risk for breast cancer relapse. (2009) (1)
Epirubicin, cyclophosphamide, and UFT plus oral calcium folinate in advanced breast cancer. (1999) (1)
471 Capecitabine in older patients ⩾70 yrs with locally advanced or metastatic breast cancer (2010) (1)
Echo/Doppler evaluation of 137 normal aortic allografts: comparison with new generation bileaflet mechanical and stentless xenograft prostheses (2002) (1)
Impact of delayed adjuvant chemotherapy: The Royal Marsden Hospital (RMH) experience. (2019) (1)
PHASE-I STUDIES WITH CB3717 (N-(4-(N-AMINO-4-HYDROXY-6-QUINAZOLINLY)METHYL)PROP-2-YNYLAMINO)BENZOYL)-L-GLUTAMIC ACID) (1983) (1)
Clinical outcomes in patients with triple negative or HER2 positive lobular breast cancer: a single institution experience (2022) (1)
Vindesine as a single agent and in combination with adriamycin in the treatment of metastatic breast carcinoma. (1980) (1)
Early Acquired Resistance to Endocrine Therapy: Extending the Neoadjuvant Model. (2009) (1)
Aminoglutethimide in the management of advanced breast cancer. (1980) (1)
Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy? (2009) (1)
Adjuvant chemotherapy for early breast cancer (1983) (1)
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study (2022) (1)
Prophylactic cranial irradiation for small-cell lung cancer (1996) (1)
Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer (2021) (1)
29 Results of independent review of 374 patients with non-small cell lung cancer (NSCLC) treated with gemcitabine (Gemzar®) (1997) (1)
Abstract P3-11-05: Neoadjuvant chemotherapy in invasive lobular breast carcinoma: Comparison of response, surgery and disease free survival with invasive ductal carcinoma (2015) (1)
Genomic Instability and TP53 Genomic Alterations Associate With Poor Antiproliferative Response and Intrinsic Resistance to Aromatase Inhibitor Treatment (2019) (1)
Predictive Biomarkers and Personalized Medicine A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer (2010) (1)
Designing adjuvant treatment based on biological measurements in the neoadjuvant setting (2010) (1)
Pre-operative chemotherapy in patients with resectable non-small cell lung cancer: The MRC LU22/NVALT/EORTC 08012 multicentre randomised trial (2007) (1)
Safety and efficacy of eribulin mesylate (EM) in patients with advanced breast cancer: The Royal Marsden experience. (2014) (1)
A randomised phase II trial of pre-operative navelbine/epirubicin (NE) versus navelbine/mitozantrone (NM) versus adriamycin/cyclophosphamide (AC) for early breast cancer (2001) (1)
Whether or not to give adjuvant chemotherapy for breast cancer. (1988) (1)
Long-term survival after hepatic resection for metastatic breast cancer: a case report. (1998) (1)
Determination of the rates of neurological toxicity associated with the use of dose-dense (DD) paclitaxel-containing schedules in patients with early breast cancer (2008) (1)
Clinical study and pharmacokinetics of lonidamine in advanced non-small cell lung cancer. (1991) (1)
Recent advances in the treatment of breast cancer (2004) (1)
Pemetrexed (Alimta): Advancing the treatment of malignant pleural mesothelioma, non-small cell lung, pancreas, and other cancers - Introduction (2003) (1)
2MO Abemaciclib in high risk early breast cancer (2020) (1)
Primary medical chemotherapy with continuous infusional 5-fu (F), epirubicin (E) and cisplatin (P) for large operable breast cancer: a very active new regimen (1993) (1)
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials. (2009) (1)
Molecular effects of anastrozole (A) and tamoxifen (T) alone and combined (C) in the IMPACT trial of neoadjuvant treatment of primary breast cancer. (2004) (1)
LBA5_PR Abemaciclib in high risk early breast cancer (2020) (1)
OT2-03-04: A Trial Model for the Future in the Search for Personalised Medicine – The UK POETIC and EPHOS-B Perioperative Trials Experience. (2011) (1)
Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas (2016) (1)
Abstract P2-02-01: Withdrawn (2018) (0)
MS4-2: Preoperative Endocrine Therapy: New Approaches. (2011) (0)
Letter: Cause of early death in acute leukaemia. (1973) (0)
Abstract LB-222: Lapatinib has antiproliferative effects in both HER2 positive (+) and HER2 negative (-) breast cancer (BC): results from the MAPLE short-term pre-surgical trial (CRUK E/06/039) (2012) (0)
Abstract S1-04: Exome sequencing of post-menopausal ER+ breast cancer (BC) treated pre-surgically with aromatase inhibitors (AIs) in the POETIC trial (CRUK/07/015) (2015) (0)
Pre-operative endocrine therapy: focus on the clinical and biological results of the IMPACT trial (2006) (0)
Chemotherapy of advanced stage non-SCLC-Impact on quality of life and symptom control (1997) (0)
PHASE-II AND PHASE-III STUDIES WITH CARBOPLATIN (JM8, CBDCA) (1984) (0)
71. Infusional 5-fluorouracil (F) with epirubicin (E) and carboplatin (ECarboF) in advanced/metastatic breast cancer (ABC) — an outpatient regimen with less toxicity than ECF? (1995) (0)
Carcinoma of the breast. (1995) (0)
Autologous bone marrow rescue is unnecessary after high-dose cyclophosphamide (7 g/m2) (1984) (0)
Status of adjuvant endocrine therapy for breast cancer (2014) (0)
Abstract PD5-05: Genomic instability and poor antiproliferative response to aromatase inhibitor treatment: A POETIC study (2018) (0)
New Therapies With Old Drugs (1984) (0)
939 Elevations of LFTS with gemcitabine are mild, transient and rarely result in withdrawal or dose adjustment (1995) (0)
O-28 The use of mitomycin C, vinblastine, and cisplatin (MVP) chemotherapy in patients with malignant mesothelioma — Outcome and predictive factors (2003) (0)
Time and chemotherapy treatments trends in the elderly (age>70) with lung cancer in a single UK cancer centre (2004) (0)
Abstract 3608: Molecular fingerprint sequencing for minimal residual disease detection in breast cancer (2018) (0)
Abstract P4-12-15: Long term outcome with trastuzumab in HER2-positive metastatic breast cancer: A retrospective analysis at The Royal Marsden Hospital, with a median 6 years follow up (2013) (0)
Autoimmunity and Benefit from Trastuzumab Treatment in Breast Cancer: Results from the HERA Trial (2019) (0)
The role of adjuvant systemic therapy in patients with operable breast cancer (2014) (0)
6502 ORAL Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): The MRC LU22/ NVALT 2/EORTC 08012 multi-centre randomised trial (2007) (0)
B2-02: Pre-operative chemotherapy in patients with resectable non-small cell lung cancer (NSCLC): The MRC LU22 / NVALT / EORTC 08012 multi-centre randomised trial (2007) (0)
Early enrichment of ESR1 mutations and the impact on gene expression in primary breast cancer treated with aromatase inhibitors in the pre-surgical setting (2019) (0)
Abstracts reprinted from the journal of clinical oncology (2006) (0)
PHASE-II STUDY OF CB3717 IN ADVANCED BREAST-CANCER (1985) (0)
A poetic story: lessons learnt from the world's largest breast cancer window of opportunity study (2015) (0)
Current topics Management of Hodgkin ' s disease in childhood (0)
Adjuvant aminoglutethimide for post-menopausal women with primary breast cancer: Analysis of eight years (1992) (0)
Lapatinib in HER2+ early breast cancer: Quality of life analysis. (2012) (0)
Serum and intra-tumoural tamoxifen concentrations following short-term therapy in human primary breast cancer (1992) (0)
Abstract P1-02-01: Circulating tumor DNA analysis to predict relapse and overall survival in early breast cancer – Longer follow-up of a proof-of-principle study (2017) (0)
S31 Continuous infusional chemotherapy as pre-operative and as adjuvant treatment in early breast cancer (1998) (0)
DO FUSED EYELIDS INDICATE INEVITABLE NEONATAL DEATH? (1983) (0)
Phase I study of the biodistribution, pharmacokinetics and immunogenicity of 111In-hCTMO1 (CDP671) ± predosing with unlabelled hCTMO1 in patients (pts) with lung cancer (1997) (0)
Use of an antiosteolytic agent in treatment of patients with bone metastases from breast cancer. (1980) (0)
Is S urgery N ecessary A fter C omplete C linical R emission Following N eoadjuvant C hemotherapy f or E arly B reast C ancer (2003) (0)
Central nervous system (CNS) disease during trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer (ABC): A single institution experience (2016) (0)
PHASE-I CLINICAL-TRIAL OF CB3717 ((N-(4-(N-((2-AMINO-4-HYDROXY-6-QUINAZOLINYL)METHYL)PROP-2-YNYLAMINO)BENZOYL)-L-GLUTAMIC ACID) (1984) (0)
The response of human tumour cells to radiation and cytotoxic drugs (1978) (0)
Abstract P1-08-03: Prediction of response to neoadjuvant chemotherapy in estrogen receptor positive (ER+) breast cancer by IHC4 or Ki67 alone (2013) (0)
Primary chemotherapy for early breast cancer: A revolution in progress (1997) (0)
Time and chemotherapy treatments trends in the elderly (age>70) with lung cancer in a single UK cancer centre. (2004) (0)
Recognizing the Place of Trials With Treatment of Physician's Choice As the Control Arm Reply (2015) (0)
Protracted infusional chemotherapy in breast cancer: the Royal Marsden Hospital experience. (1995) (0)
Debate: tailored targeted therapy for all - a realistic and worthwhile objective? Introduction to Session 2 (2009) (0)
De-escalation and escalation of breast cancer treatment (2017) (0)
Survival in advanced breast cancer: Author's reply. (1994) (0)
635 A study of SRL 172 (mycobacterium vaccae) as the first component of a tumour vaccine with immunological changes and clinical activity in patients with lung cancer (1997) (0)
UK TACT trial results - does everyone need adjuvant taxanes? (2008) (0)
Abstract P2-01-10: Detection of ctDNA following surgery predicts relapse in breast cancer patients receiving primary surgery (2022) (0)
Abstract P6-11-11: Trastuzumab beyond Progression in HER2-Positive Advanced Breast Cancer: The Royal Marsden Experience (2010) (0)
Chemotherapy for breast cancer given during pregnancy: A case serie. (2004) (0)
AMINOGLUTETHIMIDE IN BREAST CANCER (1978) (0)
Trastuzumab for Early Breast Cancer: Hope or Hype? (2006) (0)
Radiotherapy of lung cancer. Discussion (1995) (0)
Avoidance of Negative Results in Adjuvant Endocrine Therapy Trials for Estrogen Receptor-Positive Breast Cancer Reply (2017) (0)
Breast cancer. (2005) (0)
Chemosensitivity Studies on Human Tumour Cells from a Pancreatic Carcinoma Xenograft 1 (1979) (0)
Radiotherapy alone following a complete response to neoadjuvant chemotherapy in operable breast cancer (2004) (0)
O-251 Weight loss and anaemia are poor prognostic factors for patients with lung cancer receiving chemotherapy — will modification of these prognostic factors become a new standard of care? (2003) (0)
353 Safety of letrozole and tamoxifen monotherapy: updated BIG 1-98 (2010) (0)
Radiation induced angiosarcoma of the breast – A growing challenge in the era of breast conserving surgery (2018) (0)
687 Oestrogen receptor and K167 status in breast carcinomas following primary chemoendocrine therapy (1995) (0)
Chemotherapy for breast cancer given during pregnancy: A case serie (2004) (0)
Cancer Therapy: Clinical Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer (2011) (0)
Is pathologic complete remission a useful measure of response to novel therapies in neoadjuvant trials? (2006) (0)
397 Extreme loss of immunoreactive phosphoproteins during routine fixation of primary breast cancer (2010) (0)
Abstract P3-13-01: Withdrawn (2018) (0)
Progesterone receptor levels are associated with time to aromatase inhibitor treatment failure in estrogen receptor-positive advanced breast cancer. (2009) (0)
Comment on: Neoadjuvant versus adjuvant systemic treatment in breast cancer : A meta-analysis. Authors' reply (2005) (0)
Abstract P4-02-01: High-depth sequencing of circulating tumor DNA to interrogate the genetics of residual micro-metastatic disease prior to relapse in early breast cancer (2015) (0)
5038 Sternal/para-sternal resection for parasternal local recurrence in breast cancer (2009) (0)
MULTIMODAL THERAPY FOR STAGE-II BREAST CANCER (1978) (0)
Goals of treatment for patients with metastatic breast cancer. (2006) (0)
Abstract P4-01-01: Molecular residual disease detection with circulating tumor DNA analysis predicts relapse in patients with early stage breast cancer (2019) (0)
Comment on: Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent Human Epidermal Growth Factor Receptor-Targeted Therapy. Authors' reply (2007) (0)
88 MVP (Mitomycin-C, Vinblastine and Cisplatin) chemotherapy in small cell lung cancer (SCLC) (1995) (0)
CENTRAL-VENOUS-PRESSURE MEASUREMENT (1971) (0)
Rupture of the thoracic duct following treatment of mediastinal seminoma. (1994) (0)
O-079 Early versus delayed chemotherapy in symptomatically stableor asymptomatic patients with malignant mesothelioma — A randomised trial with survival and quality of life data (2005) (0)
Abstract P2-10-02: The impact of intrinsic subtypes and molecular features on aromatase inhibitor induced reduction of proliferation marker of Ki67 in primary ER+ breast cancer: A POETIC study (CRUK/07/015) (2017) (0)
Adjuvant chemotherapy for early breast cancer. (1983) (0)
Combination of an egfr inhibitor with an endocrine agent and treatment of breast cancer (2009) (0)
CAUSE OF EARLY DEATH IN ACUTE LEUKÆMIA (1976) (0)
Primary medical (neoadjuvant) chemotherapy with continuous infusional 5-FU (F), epirubicin (E) and cisplatin (P) for large operable breast cancer: A very active new regimen (1993) (0)
Abstract P3-03-14: Clinical utility of one-step nucleic acid amplification (OSNA) in axillary surgery after neoadjuvant chemotherapy (NAC) (2019) (0)
Primary hepatic cryptococcosis. (1983) (0)
Tamoxifen (T) versus aminoglutethimide (AG) versus combined tamoxifen and aminoglutethimide in advanced breast cancer (1981) (0)
IN14 Bisphosphonates in the adjuvant setting: ready for prime time? (2012) (0)
Reply to C. Twelves et Al. (2015) (0)
Response of breast carcinoma to chemotherapy using dynamic MR mammography: Preliminary observations. (1997) (0)
Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study (2022) (0)
0-37. Retention of functional oestrogen receptor at relapse on tamoxifen: implications for second-line endocrine therapy (1997) (0)
Abstract PD15-06: Estrogen receptor expression thresholds by IHC and mRNA for Ki67 response to aromatase inhibition: A POETIC study (2022) (0)
Hormonal therapy: introduction. (2003) (0)
Advances in endocrine therapy and its implications for translational research (2009) (0)
Changes in expression of hormone-regulated and proliferation-associated genes across the menstrual cycle in oestrogen receptor-positive breast cancer (2020) (0)
Systemic medical treatment before surgery in patients with operable breast cancer (1989) (0)
Abstract P2-09-02: True effect of aromatase inhibitor (AI) treatment on global gene expression (expr) changes in postmenopausal ER+ breast cancer (BC) patients: A POETIC study (CRUK/07/015) (2017) (0)
Peak-flow meter versus peak-flow gauge. (1974) (0)
367 Infusional 5-fluorouracil (F) with epirubicin (E) and carboplatin (ecarbof) in advanced/metastatic breast cancer (ABC)—can carbo replace cisplatin (C)? (1995) (0)
Responses: Re: Treatment of Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer Xenografts With Multiagent Human Epidermal Growth Factor Receptor-Targeted Therapy (2007) (0)
Locally Advanced Breast Cancer (2009) (0)
Final overall survival results and effect of prolonged (a parts per thousand yen1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial (2011) (0)
Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer. (2006) (0)
Treatment and prognosis of leptomeningeal disease secondary to metastatic breast cancer: a single-centre experience (2017) (0)
So you want to train in medical oncology. (1997) (0)
New approaches to the management of early breast cancer (2010) (0)
Proceedings of the Satellite Symposium "ATurning Point in Adjuvant Therapy: Optimizing the Use of Aromatase Inhibitors" at the 5th European Breast Cancer Conference, Nice, France, 22 March 2006 - Introduction (2006) (0)
A phase II clinical study of mAMSA in small cell carcinoma of the lung (2004) (0)
Long-term hazard of recurrence in HER2+ breast cancer patients untreated with anti-HER2 therapy (2015) (0)
Adjuvant treatment in breast cancer. (1992) (0)
Long-term Outcome and Prognostic Value of Ki67 after Perioperative Endocrine Therapy in Postmenopausal Women with Hormone Sensitive Early Breast Cancer: The POETIC Randomised Trial (2020) (0)
26PGENE EXPRESSION OF ESR1, PGR AND HER2 IN LYMPH NODE HOMOGENATES AND CONCORDANCE WITH IHC IN PRIMARY BREAST TUMOURS (2014) (0)
Abstract P5-18-02: Selective Crossover in Randomized Trials of Adjuvant Trastuzumab for Breast Cancer: Coping with Success (2012) (0)
77 Age is not an adverse predictive factor in the treatment of small cell lung cancer (1997) (0)
chemotherapytreatment of early breast cancer. III (2007) (0)
Abstract P4-18-03: IBCSG BIG 1-98 study: The long-term follow-up experience: (2015) (0)
Agranulocytosis associated withaminoglutethimide: Pharmacological andmarrow studies (1986) (0)
Abstract PS18-10: Intratumoural heterogeneity in PgR expression: Molecular and prognostic significance (2021) (0)
Difficult Decisions Whether or not to give adjuvant chemotherapy for breast cancer (2008) (0)
Proceedings: Studies on the radiosensitivity of human bone marrow and human tumour xenografts using an agar diffusion chamber technique for assaying clonogenic cells. (1976) (0)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial (2018) (0)
Oestrogen receptor expression in tamoxifen resistant human breast cancer (1993) (0)
WHO SHOULD TREAT CANCER? (1981) (0)
Exon S Deletion Variant Estrogen Receptor Messenger RNA Expression in Relation to Tamoxifen Resistance and Progesterone Receptor / pS 2 Status in Human Breast Cancer ' (0)
Abstract PD15-02: HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer (2022) (0)
Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial. (2018) (0)
MicroArrays comparative genomic hybridisation (aCGH) and response to neoadjuvant chemotherapy (CT) in breast cancer (BC) (2005) (0)
158PDAdjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06) (2017) (0)
The prognostic implications of chemotherapy in the treatment of breast cancer. (1996) (0)
The role of the nurse in infusional chemotherapy in patients with early breast cancer (1993) (0)
76 Clinical benefit from palliative chemotherapy in non-small cell lung cancer (NSCLC) extends to the elderly and those with poor prognostic factors (1997) (0)
Erratum to: Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer (2014) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Ian Edward Smith?

Ian Edward Smith is affiliated with the following schools: